Songwen Zhou

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4.1K citations

Medicine, Oncology, Pharmacology +10

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 468 citations

Medicine, Oncology, Pharmacology +14

MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer

Bing Li, Shengxiang Ren, Xuefei Li et al. · Lung Cancer · 2013 · 178 citations

Medicine, Molecular Biology, Oncology +14

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 120 citations · Full text

Medicine, Oncology, Pharmacology +14

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).

Caicun Zhou, Yi‐Long Wu, Xiaoqing Liu et al. · Journal of Clinical Oncology · 2012 · 79 citations

Medicine, Pharmacology, Cancer Pharmacology +7